SCOPUS (SCOring system for Prediction of response to omalizUmab in patients with chronic Spontaneous urticaria)
Aim: In this multicenter study, we aim to develop a scoring system based on the retrospective analysis of available “real-world” datasets of CSU patients worldwide including baseline/pretreatment data on demographic information, CSU clinical characteristics and laboratory parameters, and information on the response to omalizumab at follow-up.
Project lead: Pavel Kolkhir
Steering Committee: 3-5 persons will be recruited to the SC before the data analysis based on the highest number of data entries contributed.
Project advisor: Marcus Maurer
Status: Global Rollout extended until October 30, 2024. Some exceptions with a short prolongation are possible upon request if justified, but please let us know in advance how much time you need.
Number of patients included: minimum 1000 pictures (aim)
Number of UCAREs: tba
For enquiries about this project, please reach out to: Dr. Pavel Kolkhir at pavel.kolkhir(at)charite.de